Inclusion criteria

For inclusion in the program patients must fulfill the following criteria:

- Provision of informed consent prior to any program specific procedures

- Female patients ≥ 18 years of age and has platinum-sensitive relapsed high grade epithelial ovarian, primary peritoneal or fallopian tube cancer

- Patient is in response (complete response or partial response) following platinum-based chemotherapy.

- Patients must have normal organ and bone marrow function measured within 28 days prior to administration of program treatment.

- Postmenopausal or evidence of non-childbearing status for women of childbearing potential.

Exclusion criteria:

Patients should not enter the program if any of the following exclusion criteria are
fulfilled:

- Patients with a known hypersensitivity to olaparib or any of the excipients of the product.

- Concomitant use of known strong CYP3A inhibitors or moderate CYP3A inhibitors.

- Concomitant use of known strong or moderate CYP3A inducers. The required washout period prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.

- Patient with moderate or severe hepatic impairment.

- Breast feeding women.